GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05695976 |
Recruitment Status :
Recruiting
First Posted : January 25, 2023
Last Update Posted : April 17, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Glioblastoma Glioma, Malignant |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL) |
Actual Study Start Date : | April 18, 2023 |
Estimated Primary Completion Date : | January 2029 |
Estimated Study Completion Date : | January 2029 |
Group/Cohort |
---|
Pilot
The first 20 patients accrued to this study will be assayed to validate the performance of the assays developed by Personalis. This pilot sub-study will be analyzed in a "blinded" manner without clinical information.
|
Full Study
The remaining 80 patients accrued to this study (after the initial 20 patients accrue to the "Pilot" cohort).
|
- Median cf/ctDNA concentration at pre- and post-radiation, as well as median change in ct/ctDNA concentration [ Time Frame: 6 months ]Identify and describe changes in the cell free DNA (cfDNA) sequencing profiles of patients diagnosed with GBM in pre- versus post-radiation therapy samples, and to assess the association between these changes and clinical outcome, including progression free and overall survival
- Median levels of cfDNA collected longitudinally after completion of radiation [ Time Frame: 6 months ]Identify and describe changes over time after radiotherapy in the cfDNA sequencing profiles of patients diagnosed with GBM, and to assess the association between these longitudinal changes in cfDNA and clinical outcome, including progression free and overall survival
- Characterize the fragmentomic landscape of GBM [ Time Frame: 6 months ]Median number of ctDNA fragments obtained from tumor tissue, pre-radiation serum specimen, and post-radiation serum specimen, and healthy controls.
- Spearman correlation between clinical descriptors and measures of ctDNA [ Time Frame: 6 months ]Assess the association between degree and frequency of ctDNA shedding and clinical characteristics, such as molecular findings, histopathological characteristics, corticosteroid use, and bevacizumab use.
- Median and range for measures of tumor immune infiltration [ Time Frame: 6 months ]Quantify the level of immune infiltration in the tumor, and assess its association with progression-free survival (PFS), overall survival (OS), and ctDNA detection.
- Hazard ratio for the relationship between chromosomal instability and OS or PFS [ Time Frame: 6 months ]Assess the prognostic value of chromosomal instability/CAN burden, and assess its association with ctDNA from plasma.
- Spearman correlation between ctDNA and peripheral T cell function, autoantibodies. [ Time Frame: 6 months ]Determine if peripheral T cell function and stemness or autoantibodies are association with ctDNA levels, or TME composition.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Age ≥ 18 years
- Patients newly diagnosed with malignant glioma, IDH wildtype who have undergone surgical resection for their tumor and who are planned for standard of care radiation therapy with concurrent temozolomide (i.e., at least 59 Gy in 30 fractions over 6 weeks)
- Patients must have leftover tissue available from the surgical resection of their tumor available to request for this research.
- Able to undergo MRI of brain with and without contrast
- Signed informed consent approved by the Institutional Review Board (IRB)
Exclusion Criteria:
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05695976
Contact: Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 919-684-5301 | dukebrain1@dm.duke.edu | |
Contact: Stevie Threatt | 919-684-5301 | dukebrain1@dm.duke.edu |
United States, North Carolina | |
The Preston Robert Tisch Brain Tumor Center at Duke University | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Mustafa Khasraw, MBChB, MD, FRCP, FRACP 919-684-5301 dukebrain1@dm.duke.edu | |
Contact: Stevie Threatt 919-684-5301 dukebrain1@dm.duke.edu |
Principal Investigator: | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Duke University |
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT05695976 |
Other Study ID Numbers: |
Pro00110247 |
First Posted: | January 25, 2023 Key Record Dates |
Last Update Posted: | April 17, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Khasraw Glioblastoma Glioma |
Pro00110247 GRETEL Duke |
Glioblastoma Glioma Astrocytoma Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |